Cover Image

Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA

Saved in:

Bibliographic Details
Main Authors:	Timothy Fitzgerald (Author), Maryia Zhdanava (Author), Dominic Pilon (Author), Aditi Shah (Author), Patrick Lefebvre (Author), Steven R. Feldman (Author)
Format:	Book
Published:	Adis, Springer Healthcare, 2023-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Timothy Fitzgerald, et al.
Published: (2023)

Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States
by: Maryia Zhdanava, et al.
Published: (2024)

Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
by: Andrew Blauvelt, et al.
Published: (2023)

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
by: Li Y, et al.
Published: (2022)

Efficacy and safety of cyclosporin, adalimumab and secukinumab in the treatment of nail psoriasis
by: Zhanhan TANG, et al.
Published: (2023)

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain
by: Johansson E, et al.
Published: (2018)

Hair whitening in a patient with psoriasis on adalimumab reversed after switching to ixekizumab
by: Annunziata Raimondo, MD, et al.
Published: (2021)

Secukinumab: Rapid Efficacy in Psoriasis After Primary Failure With Ustekinumab and Adalimumab
by: Aline Lissa Okita, et al.
Published: (2020)

T cell epitope mapping of secukinumab and ixekizumab in healthy donors
by: Sebastian Spindeldreher, et al.
Published: (2020)

Comparision of the efficacy and safety between Secukinumab and Adalimumab in the treatment of the moderate to severe plaque psoriasis
by: Dandan HU, et al.
Published: (2023)

Guselkumab - In Psoriasis and Beyond
by: Aditya Kumar Bubna, et al.
Published: (2024)

Adalimumab-induced paradoxical pustular psoriasis and alopecia successfully treated with ixekizumab in a patient affected by hidradenitis suppurativa
by: Carlo Alberto Vignoli, et al.
Published: (2023)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021)

Treatment Patterns, Acute Healthcare Resource Use, and Costs of Patients with Treatment-Resistant Depression Completing Induction Phase of Esketamine in the United States
by: Lisa Harding, et al.
Published: (2024)

Guselkumab Reduces Disease- and Mechanism-Related Biomarkers More Than Adalimumab in Patients with Psoriasis: A VOYAGE 1 Substudy
by: Andrew Blauvelt, et al.
Published: (2024)

Effectiveness and Drug Survival of Ixekizumab and Secukinumab in Patients with Moderate to Severe Plaque Psoriasis: Real-World Data from Bucharest, Romania
by: Bucur S, et al.
Published: (2024)

Guselkumab for the treatment of psoriasis - evidence to date
by: Miguel Nogueira, et al.
Published: (2019)

Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab
by: Wechter T, et al.
Published: (2018)

Erythrodermic psoriasis after discontinuation of ixekizumab
by: Kathryn Anne Potter, MD, et al.
Published: (2018)

Successful treatment of generalized pustular psoriasis with guselkumab
by: Martina Part
Published: (2024)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
by: Yolanka Lobo, BPhysio, MBBS, et al.
Published: (2020)

Secukinumab in generalized pustular psoriasis
by: Shraddha Madanagobalane
Published: (2018)

Secukinumab Therapy in Psoriasis Management
by: Ira Yunita, et al.
Published: (2022)

Differential Pharmacodynamic Effects on Psoriatic Biomarkers by Guselkumab Versus Secukinumab Correlate with Long-Term Efficacy: An ECLIPSE Substudy
by: Andrew Blauvelt, et al.
Published: (2024)

Rapid Remission of Sunburn-Induced Guttate Psoriasis with Guselkumab
by: Erin Bartholomew, et al.
Published: (2023)

Description of the Clinical Case of Adalimumab and Secukinumab Therapy of a Patient with Psoriatic Arthritis
by: V. V. Didenko, et al.
Published: (2021)

Long-term effectiveness and safety of ixekizumab in the treatment of 14 patients with a history of chronic erythrodermic psoriasis who failed prior secukinumab: A bicentric retrospective study
by: Yang Lo, et al.
Published: (2021)

Speed and Cumulative Responses According to Body Regions in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Ixekizumab (Interleukin-17A Antagonist) versus Guselkumab (Interleukin-23p19 Inhibitor)
by: Melinda Gooderham, et al.
Published: (2024)

IL-17A Inhibitor Switching - Efficacy of Ixekizumab Following Secukinumab Failure. A Single-center Experience
by: Shany Sherman, et al.
Published: (2019)

Ixekizumab for the treatment of acrodermatitis continua of hallopeau and inverse psoriasis
by: Rui Yuan Xia, et al.
Published: (2023)

The Successful Treatment of a Case of Linear Psoriasis with Ixekizumab
by: Sara Ghoneim, et al.
Published: (2017)

The significance of secukinumab in the treatment of plaque psoriasis
by: Marta Kasprowicz-Furmańczyk, et al.
Published: (2022)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
by: Martora F, et al.
Published: (2023)

Plantar pustules in a psoriasis patient during the guselkumab therapy
by: Shinsuke Nakazawa, et al.
Published: (2021)

Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Arm (aIMM) Study
by: Richard B. Warren, et al.
Published: (2024)

Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence
by: Jashin J. Wu, et al.
Published: (2020)

A Patient with Adalimumab-Induced Refractory Paradoxical Palmoplantar Pustulosis Was Successfully Treated by Ixekizumab: A Case Report
by: Shao XY, et al.
Published: (2023)

Switching to ixekizumab improves adalimumab‐induced interstitial lung disease in patients with psoriatic arthritis: A case report
by: Hideki Hayashi, et al.
Published: (2021)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
by: Matteo Megna, MD, et al.
Published: (2023)

Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
by: Kazemi T, et al.
Published: (2017)